^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    TP53 (Tumor protein P53)

    i
    Other names: TP53, Tumor Protein P53, Cellular Tumor Antigen P53, Phosphoprotein P53, Tumor Protein P53, Antigen NY-CO-13, Transformation-Related Protein 53, Mutant Tumor Protein 53, P53 Tumor Suppressor, Tumor Suppressor P53, Tumor Protein 53, BMFS5, TRP53, BCC7, LFS1
    1d
    TERTp Mutation and its Prognostic Value in Glioma Patients Under the 2021 WHO Classification: A Real-World Study. (PubMed, Cancer Med)
    In the IDH-mutant subgroup, it tended to co-occur with CIC and FUBP1 alterations, while being mutually exclusive with ATRX and TP53 alterations. These correlations may further refine prognostic predictions.
    Journal • Real-world evidence
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • TERT (Telomerase Reverse Transcriptase) • ATRX (ATRX Chromatin Remodeler) • FUBP1 (Far Upstream Element Binding Protein 1)
    |
    KRAS mutation • EGFR mutation • MET mutation • TERT mutation
    2d
    Retrospective analysis of clinical and molecular characteristics as prognostic factors in adult T-cell lymphoblastic lymphoma. (PubMed, Am J Cancer Res)
    T-LBL is characterized by high-frequency gene mutations across multiple signaling pathways. Mediastinal invasion (70.80%) and extranodal involvement (39.33%) were prevalent in Chinese patients and were associated with poor prognosis. Combined assessment of clinical and molecular features allows for improved prognostic stratification and facilitates the development of targeted therapies for high-risk patients.
    Retrospective data • Journal
    |
    TP53 (Tumor protein P53) • NOTCH1 (Notch 1) • JAK1 (Janus Kinase 1) • JAK3 (Janus Kinase 3) • PHF6 (PHD Finger Protein 6)
    |
    TP53 mutation • JAK3 mutation • PHF6 mutation
    2d
    Recent Perspectives on Anticancer Potential of Coumarin Against Different Human Malignancies: An Updated Review. (PubMed, Food Sci Nutr)
    These molecular pathways demonstrate coumarins' potential as an interesting option for the development of novel anticancer treatments. More studies are needed to completely understand their modes of action and maximize their therapeutic efficacy.
    Review • Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
    2d
    Exploring the Anticancer Effect of Artemisia herba-alba on Colorectal Cancer: Insights From Eight Colorectal Cancer Cell Lines. (PubMed, Food Sci Nutr)
    These findings highlight the promising anticancer potential of Artemisia herba-alba as a valuable resource for innovative CRC treatments. Further research is warranted to elucidate its specific anticancer characteristics and explore its potential incorporation into future cancer therapy approaches.
    Preclinical • Journal
    |
    TP53 (Tumor protein P53) • CDK1 (Cyclin-dependent kinase 1) • CCNB1 (Cyclin B1)
    2d
    Distinctive role of DICER1 mutations in distant metastatic thyroid cancer. (PubMed, Chin J Cancer Res)
    Mutation of DICER1 gene is a non-negligible molecular event and it may represent an aggressive subset of FDTCs. DICER1 has RAS-like clinical characteristics and DICER1-mutant tumors exhibit more aggressive clinical behaviors compared with those with BRAFV600E and RET fusions.
    Journal
    |
    TP53 (Tumor protein P53) • RET (Ret Proto-Oncogene) • RAS (Rat Sarcoma Virus) • DICER1 (Dicer 1 Ribonuclease III)
    |
    TP53 mutation • BRAF V600E • BRAF V600 • RET fusion • RAS mutation • RET mutation
    2d
    Adequacy of EUS-guided fine-needle aspiration and fine-needle biopsy for next-generation sequencing in pancreatic malignancies: A systematic review and meta-analysis. (PubMed, Endosc Ultrasound)
    In the majority of cases, EUS-FNA/FNB can acquire adequate sample for NGS and identify tumor-specific mutations in patients with pancreatic malignancies. Strict pre-analysis screening criteria may negatively impact the sample adequacy and the success rate for NGS.
    Retrospective data • Journal • Next-generation sequencing
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • SMAD4 (SMAD family member 4)
    |
    TP53 mutation • KRAS mutation • SMAD4 mutation
    2d
    Atypical Small Cell Lung Cancer: A New Malignancy Characterized by Chromothripsis, Carcinoid Tumors, and Wild-type RB1 and TP53. (PubMed, Cancer Discov)
    Rekhtman and colleagues upend these assumptions by discovering an "atypical" SCLC that arises in nonsmokers with intact RB1 and TP53 loci, chromothripsis-induced oncogene amplifications on extrachromosomal DNA, and frequent synchronous carcinoid tumors. See related article by Rekhtman et al., p. 83.
    Journal
    |
    TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1)
    2d
    TP53 genetic heterogeneity in recurrent or second primary head and neck squamous cell carcinoma. (PubMed, Radiother Oncol)
    TP53 mutational heterogeneity may indicate novel molecular events rather than resistant clones' expansion or persistent disease. Surveillance and therapeutic strategies should be adjusted, especially in the case of a second primary arising in an already irradiated field.
    Journal
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    2d
    Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer (clinicaltrials.gov)
    P2, N=40, Completed, Robert L. Ferris, MD, PhD | Active, not recruiting --> Completed
    Trial completion
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Opdivo (nivolumab)
    3d
    Efficient Gene Delivery Admitted by small Metabolites Specifically Targeting Astrocytes in the Mouse Brain. (PubMed, Mol Ther)
    This approach offers a new perspective on developing gene delivery systems that specifically target astrocytes to meet the varied needs of both research and gene therapy. The innovative strategy behind gDAM is expected to provide fresh inspiration in the quest for DNA delivery to other tissues, such as skeletal muscle and skin.
    Preclinical • Journal
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • NF1 (Neurofibromin 1) • CSF2 (Colony stimulating factor 2) • IFNB1 (Interferon Beta 1)
    3d
    Comprehensive analysis of targetable mutations and tumor microenvironment in urachal cancer. (PubMed, NPJ Precis Oncol)
    Finally, we show that urachal cancer shares genomic and transcriptomic similarity with colorectal cancer compared to bladder cancer. This study provides new insights into the molecular profiles of urachal tumor samples and possibility of association with colorectal cancer that might guide future clinical trial design.
    Journal • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • GNAS (GNAS Complex Locus)
    |
    TP53 mutation • KRAS mutation • GNAS mutation
    3d
    Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group. (PubMed, Blood Cancer J)
    We integrated clinical and genetic data into the Intensive Chemotherapy Score for AML (ICSA) with 6-risk categories with significantly different remission rates and OS, validated in another cohort of 581 AML patients from a previous CETLAM protocol. In summary, we identified groups of fit patients that benefit differently from an intensive approach which may be helpful in future treatment decisions.
    Journal
    |
    TP53 (Tumor protein P53)
    3d
    Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma from Chronic Lymphocytic Leukemia Spanish Group (GELLC). (PubMed, Med Clin (Barc))
    In very frail patients, supportive treatment should be considered. In relapse/refractory patients, prior treatment, the biological risk of CLL, the duration of response (if prior finite treatment), or the reason for stopping BTKi (if prior continuous treatment) should be considered.
    Clinical guideline • Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • IGH (Immunoglobulin Heavy Locus) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    TP53 mutation • TP53 mutation + Chr del(17p)
    3d
    Optimized mammalian expression system for the ubiquitin E3 ligase E6AP/UBE3A. (PubMed, Protein Expr Purif)
    Biophysical characterization by Q-TOF confirmed sample purity while mass photometry indicated that purified E6AP forms a monomer-oligomer mixture. E6AP produced by this method is catalytically active and amenable to structural characterization by cryo-electron microscopy (cryo-EM), biochemical assays, and small molecule screening campaigns.
    Journal
    |
    TP53 (Tumor protein P53) • UBE3A (Ubiquitin Protein Ligase E3A)
    3d
    TP53 mutations and MDM2 polymorphisms in breast and ovarian cancers: amelioration by drugs and natural compounds. (PubMed, Clin Transl Oncol)
    We also highlight the potential of small molecules e.g. p53 activators like XI-011, Tenovin-1, and Nutlin-3a for the treatment of breast and ovarian cancers. The therapeutic efficacy of natural compounds in amelioration of these two types of cancers is also discussed.
    Review • Journal • BRCA Biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • MDM2 (E3 ubiquitin protein ligase)
    |
    TP53 mutation • KRAS mutation • BRCA2 mutation • BRCA1 mutation • PTEN mutation • MDM2 mutation
    3d
    Best Practice Recommendations for Endometrial Intraepithelial Neoplasia/Atypical Endometrial Hyperplasia in the Military Health System. (PubMed, Mil Med)
    Determining the optimal treatment for patients with EIN-AEH is nuanced and, within the military health care system, is complicated by varied access to expert management by a GO subspecialist. Military beneficiaries with this diagnosis present a unique challenge and warrant a standardized approach to maximize clinical outcomes.
    Journal
    |
    TP53 (Tumor protein P53) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • PMS2 (PMS1 protein homolog 2)
    |
    TP53 expression
    3d
    Abnormal p53 High-Grade Endometrioid Endometrial Cancer: A Systematic Review and Meta-Analysis. (PubMed, Cancers (Basel))
    Abnormal p53 grade 3 endometrioid endometrial cancer is more common in Asia, and it is associated with decreased overall survival and progression-free survival.
    Retrospective data • Review • Journal
    |
    TP53 (Tumor protein P53)
    |
    TP53 wild-type
    3d
    The Emerging Predictive and Prognostic Role of Aggressive-Variant-Associated Tumor Suppressor Genes Across Prostate Cancer Stages. (PubMed, Int J Mol Sci)
    Moreover, we discuss the implications of different methods used for detecting AVPC-TSG alterations and summarize factors influencing their prevalence. As our comprehension of the genomic landscape of PCa disease deepens, incorporating genomic profiling into clinical decision making will become increasingly important for improving patient outcomes.
    Review • Journal
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1)
    3d
    Cytotoxic ROS-Consuming Mn(III) Synzymes: Structural Influence on Their Mechanism of Action. (PubMed, Int J Mol Sci)
    These findings suggest that the structural differences between C1 and C2 lead to distinct redox properties and biological activities, highlighting the potential of these novel Mn(III)-based synzymes as therapeutic agents for the treatment of oxidative stress-related diseases, particularly lung cancer. Further studies are warranted to elucidate the underlying mechanisms of action and explore their clinical applications.
    Journal
    |
    TP53 (Tumor protein P53) • CASP3 (Caspase 3) • CAT (Catalase)
    |
    TP53 expression
    3d
    TP53I11 Functions Downstream of Multiple MicroRNAs to Increase ER Calcium Levels and Inhibits Cancer Cell Proliferation. (PubMed, Int J Mol Sci)
    Additionally, the chemotherapeutic agent doxorubicin (DOX) was shown to upregulate TP53I11 and enhance ER Ca2+ accumulation. These findings elucidate the central role of TP53I11 in miRNA-mediated regulation of ER Ca2+ homeostasis and suggest potential therapeutic strategies targeting ER Ca2+ upregulation for cancer intervention.
    Journal
    |
    TP53 (Tumor protein P53)
    |
    doxorubicin hydrochloride
    3d
    Histological features indicate the risk of progression of patients with Barrett's esophagus. (PubMed, Pathol Res Pract)
    These findings indicate the potential role of morphological features in assessing the risk of progression for patients with BE at the initial diagnosis. By integrating these insights into clinical practice, we may be able to optimize surveillance strategies for patients with this condition, ultimately improving patient outcomes.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    3d
    Clinicopathologic and genomic characteristics of biliary tract carcinomas with TERT promoter mutations among East Asian population. (PubMed, Pathol Res Pract)
    In conclusion, TERT mutations in biliary tract carcinomas had unique clinicopathologic and genetic characteristics. Despite its poor PFS, the concomitant presence of ERBB2 amplification and a high TMB indicated a potential for targeted therapy and immunotherapy in this specific subtype.
    Journal • Tumor mutational burden • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • TERT (Telomerase Reverse Transcriptase) • PBRM1 (Polybromo 1) • SMAD4 (SMAD family member 4)
    |
    TP53 mutation • KRAS mutation • TMB-H • HER-2 amplification • HER-2 mutation • PBRM1 mutation • TERT mutation • TERT promoter mutation
    3d
    Cabozantinib Selectively Induces Proteasomal Degradation of p53 Somatic Mutant Y220C and Impedes Tumor Growth. (PubMed, J Biol Chem)
    We also show that cabozantinib displays preferential cytotoxicity to p53Y220C-harboring cancer cells both in vitro and in vivo. This study demonstrates a novel, p53-Y220C mutant-targeted anticancer action and mechanism for cabozantinib, and provides the rationale for use of this drug in treatment of cancers that carry the p53-Y220C mutation.
    Journal
    |
    TP53 (Tumor protein P53) • USP7 (Ubiquitin Specific Peptidase 7)
    |
    TP53 mutation • TP53 Y220C
    |
    Cabometyx (cabozantinib tablet)
    3d
    MTHFR C677T rs1801133 and TP53 Pro72Arg rs1042522 gene variants in South African Indian and Caucasian psoriatic arthritis patients. (PubMed, Genet Mol Biol)
    (ii) Results for rs1042522 genotyping: Indian patients had a higher frequency of the variant Arg-allele versus healthy Indian controls (42% versus 29%; OR=1.75, 95% CI=1.07-2.86, p=0.0275). In conclusion, patients with the MTHFR rs1801133 variant T-allele have elevated CRP levels, which can be ameliorated with methotrexate.
    Journal
    |
    TP53 (Tumor protein P53) • MTHFR (Methylenetetrahydrofolate Reductase) • CRP (C-reactive protein)
    |
    MTHFR C677T
    |
    methotrexate
    3d
    Study on mechanism of Spatholobi Caulis in the treatment of the hand-foot skin reaction induced by targeted drug therapy based on network pharmacology and molecular docking: An observational study. (PubMed, Medicine (Baltimore))
    Medicagol, the active components of Spatholobi Caulis, is proved in the Hand-foot skin reaction induced by lung cancer targeted therapy by regulating multiple signaling pathways through EGFR. It is confirmed that the treatment of Hand-foot skin reaction has the characteristics of multi-component, multi-target and multi-pathway regulation.
    Observational data • Journal
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • HSP90AB1 (Heat Shock Protein 90 Alpha Family Class B Member 1)
    3d
    ATRX mutation modifies the DNA damage response in glioblastoma multiforme tumor cells and enhances patient prognosis. (PubMed, Medicine (Baltimore))
    Furthermore, additional protective factors such as younger age, female gender, combined IDH mutations, and TP53 mutations were identified. The results underscore the protective role and prognostic significance of ATRX mutations in GBM as a potential therapeutic target and biomarker for patient survival.
    Journal • Tumor mutational burden • IO biomarker
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • ATRX (ATRX Chromatin Remodeler)
    |
    TP53 mutation • ATRX mutation
    3d
    Comparative genomic analysis unveiling the mutational landscape associated with premalignant lesions and early-stage gastric cardia cancer. (PubMed, Medicine (Baltimore))
    Certain mutational characteristics involved in the occurrence and progression of GCA are already present in premalignant lesions and early-stage GCA, which can be assessed and prevented through early molecular testing. Additionally, EPHA2 mutations are more common in premalignant lesions and early-stage GCA, which provided potential biomarkers for the diagnosis and detection of premalignant lesions and early-stage GCA.
    Clinical • Journal • Tumor mutational burden
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • LRP1B (LDL Receptor Related Protein 1B) • EPHA2 (EPH receptor A2)
    3d
    Aqueous and ethanolic extracts of Moringa oleifera leaves induce selective cytotoxicity in Raji and Jurkat cell lines by activating the P21 pathway independent of P53. (PubMed, Mol Biol Rep)
    This study shows that leukemia cells (Raji and Jurkat) are more sensitive to MO's aqueous and ethanolic extracts than healthy cells. The results suggest developing MO extracts as a cutting-edge leukemia treatment.
    Preclinical • Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • BIRC5 (Baculoviral IAP repeat containing 5) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • ANXA5 (Annexin A5)
    |
    BCL2 expression • TP53 expression
    3d
    Molecular Mechanisms of Synergistic Effect of PRIMA-1met and Oxaliplatin in Colorectal Cancer With Different p53 Status. (PubMed, Cancer Med)
    In summary, our research reveals the differential molecular mechanisms of combined PRIMA-1met and L-OHP in CRC with wild type p53 and mutant p53. Our data not only demonstrate that this combined regimen exerts synergistic anti-CRC effect in vitro and in vivo, but also suggest the benefit of PRIMA-1met on prevention of L-OHP-related side effects. These findings underscore the clinical potential of PRIMA-1met-L-OHP combination therapy in CRC, offering enhanced efficacy and reduced toxicity, warranting further clinical investigation.
    Journal
    |
    TP53 (Tumor protein P53) • DLD (Dihydrolipoamide Dehydrogenase)
    |
    TP53 mutation • TP53 wild-type
    |
    oxaliplatin • eprenetapopt (APR-246)
    3d
    The expression of the lncRNAs USP30-AS1, ELFN1-AS1, GAS8-AS1, and SNHG11 in breast cancer samples from Iranian patients from 2014 to 2019: a cross-sectional study. (PubMed, BMC Res Notes)
    Elevated ELFN1-AS1 expression was associated with breast cancer that lacked P53 mutation. These changes suggest their promise as biomarkers for distinguishing between cancerous and noncancerous tissues.
    Observational data • Journal
    |
    TP53 (Tumor protein P53) • SNHG11 (Small Nucleolar RNA Host Gene 11) • USP30-AS1 (USP30 Antisense RNA 1)
    |
    TP53 mutation
    3d
    Kelch-like ECH-associated Protein 1/Nuclear Factor Erythroid 2-related Factor 2 Pathway and Its Interplay with Oncogenes in Lung Tumorigenesis. (PubMed, J Cancer Prev)
    The review highlights the context-dependent effects of NRF2, from its protective role against chemical carcinogen-induced tumor initiation to its potential promotion of tumor growth in established cancers. These findings suggest the need for nuanced, stage-specific approaches to targeting the NRF2 pathway in cancer therapy.
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • KEAP1 (Kelch Like ECH Associated Protein 1)
    3d
    Estimation of TP53 mutations for endometrial cancer based on diffusion-weighted imaging deep learning and radiomics features. (PubMed, BMC Cancer)
    A prediction model based on the GP algorithm and consisting of DL and radiomics features of DWI as well as clinical variables can effectively assess TP53 mutation in EC.
    Journal
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    3d
    Stage-specific efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNA. (PubMed, Invest New Drugs)
    Patients with EGFR-positive NSCLC in stage IVB exhibited significantly shorter PFS and OS than those in earlier stages when treated with first-line osimertinib. The prevalence of baseline TP53 mutations, EGFR amplification, and MET amplification in plasma were significantly higher in stage IVB cases, implicating them in the worse outcomes of this group.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    TP53 mutation • EGFR mutation • MET amplification • EGFR amplification • MET mutation • EGFR positive
    |
    Tagrisso (osimertinib)
    3d
    Long non-coding RNA CAR10 promotes angiogenesis of lung adenocarcinoma by mediating nuclear LDHA to epigenetically regulate VEGFA/C. (PubMed, Commun Biol)
    In addition, MYC and TP53 bonded to the promotor of CAR10 and reverse regulated its expression in LUAD cells. CAR10 regulates post-translational modification of LDHA and increases the H3K79 methylation of VEGFA/VEGFC to promote angiogenesis of LUAD, which is a potential therapeutic target for LUAD.
    Journal
    |
    TP53 (Tumor protein P53) • LDHA (Lactate dehydrogenase A) • VEGFA (Vascular endothelial growth factor A) • VEGFC (Vascular Endothelial Growth Factor C)
    3d
    Pathological variants in HPV-independent vulvar tumours. (PubMed, Sci Rep)
    The PI3K/AKT/mTOR1 pathway was affected in both the groups as well as the cell cycle regulation pathway. Similarly, the DNA repair gene POLE was found mutated in both vulvar cancer groups.
    Journal • BRCA Biomarker
    |
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA2 (Breast cancer 2, early onset) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ARID1A (AT-rich interaction domain 1A) • NOTCH1 (Notch 1) • NF1 (Neurofibromin 1) • PTCH1 (Patched 1) • CDK4 (Cyclin-dependent kinase 4) • MSH2 (MutS Homolog 2) • NOTCH2 (Notch 2) • CREBBP (CREB binding protein) • CDK2 (Cyclin-dependent kinase 2) • PSMD1 (Proteasome 26S Subunit Non-ATPase 1) • TBL1XR1 (TBL1X Receptor 1)
    |
    TP53 mutation • AKT1 amplification
    |
    Oncomine™ Comprehensive Assay v3M
    3d
    Li-Fraumeni syndrome: a germline TP53 splice variant reveals a novel physiological alternative transcript. (PubMed, J Med Genet)
    By combining these approaches, we successfully reclassified this intronic VUS as 'pathogenic', enabling appropriate genetic counselling for the patient and her family. Additionally, we identified a novel TP53 alternative transcript that is expressed in both physiological and pathological contexts, with heightened expression in the patient with LFS. This discovery provides a basis for further investigation into the role of TP53 isoforms in LFS oncogenesis.
    Journal
    |
    TP53 (Tumor protein P53)
    3d
    Computational pathology applied to clinical colorectal cancer cohorts identifies immune and endothelial cell spatial patterns predictive of outcome. (PubMed, J Pathol)
    © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland
    Journal • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • MSI (Microsatellite instability)
    |
    TP53 mutation • BRAF V600E • BRAF V600
    3d
    Chlorophyllides repress gain-of-function p53 mutated HNSCC cell proliferation via activation of p73 and repression of p53 aggregation in vitro and in vivo. (PubMed, Biochim Biophys Acta Mol Basis Dis)
    In our previous study, co-treatment with p73 activator NSC59984 and NAMPT inhibitor FK886 synergistically repressed Detroit 562 cell proliferation...Moreover, NAMPT was repressed by chlorophyllides independent of p73 status in vivo. We thus concluded that chlorophyllides have a dual anticancer function when applied to HNSCC cells with p53 gain-of-function mutation, via activation of p73 and repression of p53 aggregation.
    Preclinical • Journal
    |
    TP53 (Tumor protein P53) • CASP3 (Caspase 3) • CASP7 (Caspase 7) • NAMPT (Nicotinamide Phosphoribosyltransferase)
    |
    TP53 mutation
    |
    NSC59984
    3d
    Correlation of Histologic Features with Gene Alterations in Pleural Mesothelioma. (PubMed, Mod Pathol)
    Tumors with low tumor infiltrating lymphocytes had a higher rate of BAP1 alterations compared to tumors with higher levels of tumor infiltrating lymphocytes (67% versus 30%; p=0.002). The findings of this study enhance our understanding of the relationships among prognostically significant histologic and molecular features of DPM and provide preliminary data to support increased integration of these findings in clinical diagnosis of pleural mesothelioma.
    Journal
    |
    TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • BAP1 (BRCA1 Associated Protein 1)
    3d
    High-Risk MCL: Recognition and Treatment. (PubMed, Blood)
    These findings necessitate revisiting the prognostic impact of high-risk factors, current management strategies, new bi- and tri-specific T-cell engagers, combination therapies, novel therapeutic targets, and next-generation clinical trials for high-risk MCL patients. This article provides a comprehensive update on recognizing and managing high-risk MCL, encompassing current practices and future directions.
    Journal
    |
    TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1) • KMT2D (Lysine Methyltransferase 2D) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • NOTCH2 (Notch 2) • BIRC3 (Baculoviral IAP repeat containing 3) • CD70 (CD70 Molecule) • SP140 (SP140 Nuclear Body Protein) • MSI2 (Musashi RNA Binding Protein 2) • NFKBIE (NFKB Inhibitor Epsilon) • SOX11 (SRY-Box Transcription Factor 11) • NSD2 (Nuclear Receptor Binding SET Domain Protein 2)
    |
    TP53 mutation • MYC rearrangement
    3d
    Immune Checkpoint Blockade Delays Cancer Development and Extends Survival in DNA Polymerase Mutator Syndromes. (PubMed, Cancer Res)
    These results demonstrated the efficiency by which cells with antigenic mutations are eliminated in vivo. Finally, ICB treatment of mutator mice earlier, before observable tumors had developed delayed cancer onset, improved survival, and selected for tumors without aneuploidy, suggesting the potential of ICB in high-risk individuals for cancer prevention.
    Journal • Checkpoint inhibition • Tumor mutational burden • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • POLE (DNA Polymerase Epsilon) • POLD1 (DNA Polymerase Delta 1)
    |
    TP53 mutation • KRAS mutation • POLE mutation • TP53 deletion • POLD1 mutation • KRAS deletion
    3d
    Mutant Pattern of p53 as a Feasible Predictor of Distant Metastasis Following Curative Gastrectomy for Advanced-stage Gastric Cancer. (PubMed, J Cancer)
    The 5-year overall survival rate in patients with the p53 mutant pattern (n = 189) was worse than that in the patients with p53 wild-type (n = 189) and with significant differences (log-rank P<0.01). The study was statistically significant after Cox univariate and multivariate regression analysis, which revealed that the mutant pattern of p53 is an independent prognostic factor impacting distant metastases following curative gastrectomy for advanced-stage gastric cancer (p = 0.48).
    Journal
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • TP53 wild-type • TP53 expression